Tarsus Pharmaceuticals, Inc. TARS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s investing cash flow?
- Tarsus Pharmaceuticals, Inc. (TARS) reported investing cash flow of -$58.56M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s investing cash flow changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s investing cash flow decreased by 67.6% year-over-year, from -$34.94M to -$58.56M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s investing cash flow?
- Over 3 years (2021 to 2024), Tarsus Pharmaceuticals, Inc.'s investing cash flow has grown at a 601.5% compound annual growth rate (CAGR), from -$586K to -$202.32M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.